{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:04:37Z","timestamp":1779959077028,"version":"3.53.1"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Promethazine has long been a cornerstone in the management of nausea and vomiting (N\/V) in emergency medicine; however, its safety profile\u2014including risks of severe tissue injury and respiratory depression\u2014has prompted renewed scrutiny. Nausea and vomiting arise from complex interactions between central and peripheral pathways involving the chemoreceptor trigger zone, vagal afferents, and multiple neurotransmitter systems, including dopamine (D2), serotonin (5-HT3), histamine (H1), muscarinic (M1), and neurokinin-1 (NK1) receptors. This manuscript presents a focused narrative review and expert commentary examining the evolving role of promethazine in modern clinical practice. Drawing on regulatory guidance, contemporary literature, and institutional experience, we evaluate the risks associated with injectable promethazine and the rationale for transitioning toward safer alternatives. At our institution, removal of injectable promethazine from the formulary was guided by multidisciplinary consensus and aligned with updated safety recommendations. Alternative agents, including dopamine antagonists and 5-HT3 receptor antagonists, provide comparable or superior efficacy with improved safety profiles. Advances in antiemetic therapy now support a multimodal, receptor-targeted approach, combining agents that act on complementary pathways to improve symptom control while minimizing adverse effects. While clinical contexts such as chemotherapy-induced and postoperative nausea and vomiting differ in etiology and guideline-based management, they share overlapping receptor pathways that allow for a unified pharmacologic framework. Although intravenous promethazine remains in use in some settings, evolving safety data and regulatory guidance have led to progressive restriction and, in many institutions, elimination of its parenteral use. Given the availability of safer and more targeted therapies, the continued routine use of injectable promethazine warrants critical reassessment. This shift reflects a broader movement toward precision, safety, and evidence-based practice in antiemetic management and highlights the importance of aligning clinical practice with contemporary pharmacologic understanding.<\/jats:p>","DOI":"10.1177\/20503121261449562","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:55:37Z","timestamp":1779702937000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Moving beyond promethazine: Advancing precision in antiemetic therapy"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-8959","authenticated-orcid":false,"given":"Matthew F.","family":"Ryan","sequence":"first","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Lagasse","sequence":"additional","affiliation":[{"name":"UF Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.10.030"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001485"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2020.011"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115797"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032196"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000002"},{"key":"e_1_3_4_9_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network (NCCN)","year":"2024","unstructured":"National Comprehensive Cancer Network (NCCN). Antiemesis (Version 1.2024). NCCN Clinical Practice Guidelines in Oncology, 2024."},{"issue":"21","key":"e_1_3_4_10_2","first-page":"3903","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"26","author":"Hesketh PJ","year":"2008","unstructured":"Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2008; 26(21): 3903\u20133910.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2024.09.013"},{"key":"e_1_3_4_12_2","volume-title":"Silver Spring (MD)","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration. FDA requires updates to labeling for promethazine hydrochloride injection products. Silver Spring (MD). FDA, 2023."},{"key":"e_1_3_4_13_2","volume-title":"Horsham (PA)","author":"Institute for Safe Medication Practices","year":"2023","unstructured":"Institute for Safe Medication Practices. ISMP targeted medication safety best practices for hospitals: 2022\u20132024. Horsham (PA). ISMP, 2023."},{"key":"e_1_3_4_14_2","volume-title":"Silver Spring (MD)","author":"U.S. Food and Drug Administration","year":"2009","unstructured":"U.S. Food and Drug Administration. Promethazine injection (Phenergan): severe tissue injury including gangrene. Silver Spring (MD). FDA, 2009."},{"issue":"2","key":"e_1_3_4_15_2","first-page":"1","article-title":"Medication errors involving promethazine","volume":"3","author":"Pennsylvania Patient Safety Reporting System","year":"2006","unstructured":"Pennsylvania Patient Safety Reporting System. Medication errors involving promethazine. Pa Patient Saf Advis 2006; 3(2): 1\u20137.","journal-title":"Pa Patient Saf Advis"},{"issue":"29","key":"e_1_3_4_16_2","first-page":"717","article-title":"Adverse drug events related to promethazine","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","unstructured":"Centers for Disease Control and Prevention. Adverse drug events related to promethazine. MMWR Morb Mortal Wkly Rep 2005; 54(29): 717\u2013720.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"issue":"1","key":"e_1_3_4_18_2","first-page":"51","article-title":"Treatment of chemotherapy-induced nausea and vomiting: focus on newer agents","volume":"22","author":"Navari RM","year":"2004","unstructured":"Navari RM. Treatment of chemotherapy-induced nausea and vomiting: focus on newer agents. Cancer Invest 2004; 22(1): 51\u201356.","journal-title":"Cancer Invest"},{"issue":"2","key":"e_1_3_4_19_2","first-page":"117","article-title":"The role of dexamethasone in antiemetic regimens","volume":"13","author":"Aapro MS","year":"2005","unstructured":"Aapro MS, Molassiotis A, Dicato M, et al. The role of dexamethasone in antiemetic regimens. Support Care Cancer 2005; 13(2): 117\u2013122.","journal-title":"Support Care Cancer"},{"key":"e_1_3_4_20_2","volume-title":"Antiemetic strategies for chemotherapy-induced nausea","author":"National Institute for Health and Care Excellence (NICE)","year":"2023","unstructured":"National Institute for Health and Care Excellence (NICE). Antiemetic strategies for chemotherapy-induced nausea. NICE, 2023."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.003"},{"issue":"2","key":"e_1_3_4_22_2","first-page":"115","article-title":"5-HT3 receptor antagonists for the treatment of nausea and vomiting","volume":"1","author":"Smith HS","year":"2012","unstructured":"Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea and vomiting. Ann Palliat Med 2012; 1(2): 115\u2013120. https:\/\/doi.org\/10.3978\/j.issn.2224-5820.2012.07.07","journal-title":"Ann Palliat Med"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000163"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31826f0a0a"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04189.x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01196"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2000.108652"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2344\/anpr-67-03-14"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060505"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1384"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1080688"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"e_1_3_4_34_2","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, 2017."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-48110-6.00034-X"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-33-6009-9_36"}],"container-title":["Sage Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121261449562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121261449562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121261449562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:16:29Z","timestamp":1779956189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121261449562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"alternative-id":["10.1177\/20503121261449562"],"URL":"https:\/\/doi.org\/10.1177\/20503121261449562","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"20503121261449562"}}